Search

Your search keyword '"Otero-Candelera R"' showing total 6 results
Start Over Author "Otero-Candelera R" Publication Type Electronic Resources

Refine your results

6 results on '"Otero-Candelera R"'

1. Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE Registry

Author

Universitat Rovira i Virgili, Debourdeau, P; Bertoletti, L; Font, C; López-Núñez, JJ; Gómez-Cuervo, C; Mahe, I; Otero-Candelera, R; Adarraga, MD; López-Miguel, P; Monreal, M, Universitat Rovira i Virgili, and Debourdeau, P; Bertoletti, L; Font, C; López-Núñez, JJ; Gómez-Cuervo, C; Mahe, I; Otero-Candelera, R; Adarraga, MD; López-Miguel, P; Monreal, M

Abstract

Background: The clinical characteristics and outcomes of cancer patients with lower-limb isolated superficial vein thrombosis (SVT) have not been consistently evaluated. Methods: We used data in the RIETE registry to compare the clinical characteristics and 90-day outcomes for patients with: (1) active cancer and lower-limb SVT; (2) active cancer and lower-limb deep vein thrombosis (DVT); (3) lower-limb SVT without cancer. The primary outcomes included subsequent symptomatic SVT, DVT or pulmonary embolism (PE). Secondary outcomes were major bleeding and death. Results: From March 2015 to April 2021, there were 110 patients with cancer and SVT, 1695 with cancer and DVT, and 1030 with SVT but no cancer. Most patients in all subgroups (93%, 99% and 96%, respectively) received anticoagulants, while those with SVT received lower daily doses of low-molecular-weight heparin (114 +/- 58, 163 +/- 44, and 106 +/- 50 IU/kg, respectively). During the first 90 days, 101 patients (3.6%) developed subsequent VTE (PE 47, DVT 41, SVT 13), whereas 72 (2.5%) had major bleeding and 282 (9.9%) died. Among the three groups, 90-day events were, respectively: VTE at rates of 7.3%, 4.0% and 2.4%; major bleeding at rates of 2.7%, 3.9% and 0.3%; mortality at rates of 8.2%, 16% and 0.3%. Between D90 and D180, only one SVT recurrence and one death occurred in SVT cancer patients. In multivariable analysis, cancer was associated with subsequent VTE (HR = 2.04; 1.15-3.62), while initial presentation as SVT or DVT were not associated with a different risk. Conclusions: The risk for subsequent VTE (including symptomatic SVT, DVT or PE) was similar in cancer patients with isolated SVT than in those with isolated DVT.

Published
2023

2. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

Author

Dep Infectieziekten Immunologie, LS Celbiologie-Algemeen, Sub General Pharmaceutics, Sub Algebra,Geometry&Mathem. Logic begr., LS Pharma, dB&C I&I, van der Pol, E., Sturk, A., van Leeuwen, T., Nieuwland, R., Coumans, F., Mobarrez, F., Arkesteijn, G., Wauben, M., Siljander, P. R.M., Sánchez-López, V., Otero-Candelera, R., Ramón, L. A., Dolz, S., Vila, V., Mackman, N., Geddings, J., Mullier, F., Bailly, N., Han, J. Y., Kwaan, H. C., Weiss, I. M., Buzás, E. I., Pállinger, E., Harrison, P., Kraan, J., Hedley, B. D., LazoLangner, A., Enjeti, A., Norris, P. J., Paris, C., Susen, S., Bonnefoy, A., Delorme, I., Chandler, W. L., Hau, C., Aass, H. C.D., Connor, D., Wu, X., Dragovic, R., Uotila, L. M., Lacroix, R., Robert, S., Dep Infectieziekten Immunologie, LS Celbiologie-Algemeen, Sub General Pharmaceutics, Sub Algebra,Geometry&Mathem. Logic begr., LS Pharma, dB&C I&I, van der Pol, E., Sturk, A., van Leeuwen, T., Nieuwland, R., Coumans, F., Mobarrez, F., Arkesteijn, G., Wauben, M., Siljander, P. R.M., Sánchez-López, V., Otero-Candelera, R., Ramón, L. A., Dolz, S., Vila, V., Mackman, N., Geddings, J., Mullier, F., Bailly, N., Han, J. Y., Kwaan, H. C., Weiss, I. M., Buzás, E. I., Pállinger, E., Harrison, P., Kraan, J., Hedley, B. D., LazoLangner, A., Enjeti, A., Norris, P. J., Paris, C., Susen, S., Bonnefoy, A., Delorme, I., Chandler, W. L., Hau, C., Aass, H. C.D., Connor, D., Wu, X., Dragovic, R., Uotila, L. M., Lacroix, R., and Robert, S.

Published
2018

3. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

Author

Dep Infectieziekten Immunologie, LS Celbiologie-Algemeen, Sub General Pharmaceutics, Sub Algebra,Geometry&Mathem. Logic begr., LS Pharma, dB&C I&I, van der Pol, E., Sturk, A., van Leeuwen, T., Nieuwland, R., Coumans, F., Mobarrez, F., Arkesteijn, G., Wauben, M., Siljander, P. R.M., Sánchez-López, V., Otero-Candelera, R., Ramón, L. A., Dolz, S., Vila, V., Mackman, N., Geddings, J., Mullier, F., Bailly, N., Han, J. Y., Kwaan, H. C., Weiss, I. M., Buzás, E. I., Pállinger, E., Harrison, P., Kraan, J., Hedley, B. D., LazoLangner, A., Enjeti, A., Norris, P. J., Paris, C., Susen, S., Bonnefoy, A., Delorme, I., Chandler, W. L., Hau, C., Aass, H. C.D., Connor, D., Wu, X., Dragovic, R., Uotila, L. M., Lacroix, R., Robert, S., Dep Infectieziekten Immunologie, LS Celbiologie-Algemeen, Sub General Pharmaceutics, Sub Algebra,Geometry&Mathem. Logic begr., LS Pharma, dB&C I&I, van der Pol, E., Sturk, A., van Leeuwen, T., Nieuwland, R., Coumans, F., Mobarrez, F., Arkesteijn, G., Wauben, M., Siljander, P. R.M., Sánchez-López, V., Otero-Candelera, R., Ramón, L. A., Dolz, S., Vila, V., Mackman, N., Geddings, J., Mullier, F., Bailly, N., Han, J. Y., Kwaan, H. C., Weiss, I. M., Buzás, E. I., Pállinger, E., Harrison, P., Kraan, J., Hedley, B. D., LazoLangner, A., Enjeti, A., Norris, P. J., Paris, C., Susen, S., Bonnefoy, A., Delorme, I., Chandler, W. L., Hau, C., Aass, H. C.D., Connor, D., Wu, X., Dragovic, R., Uotila, L. M., Lacroix, R., and Robert, S.

Published
2018

4. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

Author

Dep Infectieziekten Immunologie, LS Celbiologie-Algemeen, Sub General Pharmaceutics, Sub Algebra,Geometry&Mathem. Logic begr., LS Pharma, dB&C I&I, van der Pol, E., Sturk, A., van Leeuwen, T., Nieuwland, R., Coumans, F., Mobarrez, F., Arkesteijn, G., Wauben, M., Siljander, P. R.M., Sánchez-López, V., Otero-Candelera, R., Ramón, L. A., Dolz, S., Vila, V., Mackman, N., Geddings, J., Mullier, F., Bailly, N., Han, J. Y., Kwaan, H. C., Weiss, I. M., Buzás, E. I., Pállinger, E., Harrison, P., Kraan, J., Hedley, B. D., LazoLangner, A., Enjeti, A., Norris, P. J., Paris, C., Susen, S., Bonnefoy, A., Delorme, I., Chandler, W. L., Hau, C., Aass, H. C.D., Connor, D., Wu, X., Dragovic, R., Uotila, L. M., Lacroix, R., Robert, S., Dep Infectieziekten Immunologie, LS Celbiologie-Algemeen, Sub General Pharmaceutics, Sub Algebra,Geometry&Mathem. Logic begr., LS Pharma, dB&C I&I, van der Pol, E., Sturk, A., van Leeuwen, T., Nieuwland, R., Coumans, F., Mobarrez, F., Arkesteijn, G., Wauben, M., Siljander, P. R.M., Sánchez-López, V., Otero-Candelera, R., Ramón, L. A., Dolz, S., Vila, V., Mackman, N., Geddings, J., Mullier, F., Bailly, N., Han, J. Y., Kwaan, H. C., Weiss, I. M., Buzás, E. I., Pállinger, E., Harrison, P., Kraan, J., Hedley, B. D., LazoLangner, A., Enjeti, A., Norris, P. J., Paris, C., Susen, S., Bonnefoy, A., Delorme, I., Chandler, W. L., Hau, C., Aass, H. C.D., Connor, D., Wu, X., Dragovic, R., Uotila, L. M., Lacroix, R., and Robert, S.

Published
2018

5. Survivin is a negative prognostic factor in malignant pleural effusion

Author

Universitat Rovira i Virgili, Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R, Universitat Rovira i Virgili, and Arellano-Orden E; Romero-Romero B; Sánchez-López V; Martín-Juan J; Rodríguez-Panadero F; Otero-Candelera R

Abstract

© 2018 Stichting European Society for Clinical Investigation Journal Foundation Background: Survivin is a well-known member of the inhibitor of apoptosis family, and has been related to increased tumour aggressivity, both in tissue and in pleural fluid. Objectives: In patients with malignant pleural effusion, we sought to investigate the changes in pleural fluid survivin concentrations induced by talc instillation into the pleural space. Those changes were also examined in relation to pleurodesis outcome and patient survival. Methods: We investigated 84 patients with malignant pleural effusion who underwent talc pleurodesis. Of them, 32 had breast cancer, 25 lung cancer and 27 had mesothelioma. Serial samples of pleural fluid were obtained before thoracoscopy (baseline) and 24 hours thereafter. Results: Survivin levels were successfully quantified in all pleural fluid samples, and they were significantly higher in samples obtained after thoracoscopic talc poudrage compared with baseline (P <.001). Patients with higher pleural fluid survivin levels at baseline had a significantly poorer pleurodesis outcome (P =.004). A 30 pg/mL cut-off for baseline survivin in pleural fluid predicted failure of pleurodesis with a 54% sensitivity and 79% specificity (P =.009). Moreover, median postpleurodesis survival of patients with baseline survivin levels ≥30 pg/mL was 4 months (range: 0.1-38), compared with 13 months (range: 0.1-259) in patients below that cut-off (P <.001). Conclusion: Elevated pleural fluid survivin concentrations are useful to predict failure of pleurodesis and are associated with shorter survival in patients with malignant pleural effusion.

Published
2018

6. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis

Author

Universitat Rovira i Virgili, Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Sanchez-Lopez V; de la Borbolla M; Arellano-Orden E; Suarez-Valdivia L; Marin-Romero S; Marin-Barrera L; Ruiz-Garcia A; Montero-Romero E; Navarro-Herrero S; Lopez-Campos J; Serrano-Gotarredona M; Praena-Fernandez J; Sanchez-Diaz J; Otero-Candelera R, Universitat Rovira i Virgili, and Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Sanchez-Lopez V; de la Borbolla M; Arellano-Orden E; Suarez-Valdivia L; Marin-Romero S; Marin-Barrera L; Ruiz-Garcia A; Montero-Romero E; Navarro-Herrero S; Lopez-Campos J; Serrano-Gotarredona M; Praena-Fernandez J; Sanchez-Diaz J; Otero-Candelera R

Abstract

© 2018, Cancer Research UK. Background: Optimal duration of anticoagulation for cancer-associated thrombosis (CAT) remains unclear. This study assessed D-dimer (DD) and high-sensitivity C-reactive protein (hs-CRP) levels after the withdrawal of anticoagulation treatment to predict the risk of venous thromboembolism (VTE) recurrence among patients with CAT. Methods: Prospective, multicentre study to evaluate CAT with ≥3 months of anticoagulation that was subsequently discontinued. Blood samples were taken when patients stopped the anticoagulation and 21 days later to determine the DD and hs-CRP levels. All patients were followed up for 6 months to detect VTE recurrence. Results: Between 2013 and 2015, 325 patients were evaluated and 114 patients were ultimately enrolled in the study. The mean age was 62 ± 14 years and nearly 40% had metastasis. Ten patients developed VTE recurrence within 6 months (8.8%, 95% confidence interval [CI]: 4.3–15.5%). The DD and hs-CRP levels after 21 days were associated with VTE recurrence. The subdistribution hazard ratios were 9.82 for hs-CRP (95% CI: 19–52) and 5.81 for DD (95% CI: 1.1–31.7). Conclusions: This study identified that hs-CRP and DD were potential biomarkers of VTE recurrence after discontinuation of anticoagulation in CAT. A risk-adapted strategy could identify low-risk patients who may benefit from discontinuation of anticoagulation.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results